<DOC>
	<DOCNO>NCT03048994</DOCNO>
	<brief_summary>Severe sepsis common condition high mortality morbidity . A previous meta-analysis demonstrate safety glutamine supplementation suggestion mortality morbidity benefit critically ill patient . But lack evidence recommend use intravenous glutamine supplementation population group . A randomized control trial adequately power resolve issue include future international nutrition guideline critically ill . This pilot study do prior propose local multi-center study investigate effect glutamine supplementation .</brief_summary>
	<brief_title>Glutamine Supplementation Critically Ill Patients With Severe Sepsis</brief_title>
	<detailed_description>Objective - To determine effect intravenous glutamine supplementation compare placebo critically ill patient severe sepsis - Primary outcome : 28 day mortality , Development infectious complication - Secondary outcome - Duration mechanical ventilation - Length stay ICU - Length stay hospital - 3 month survival status resumption baseline activity - 6 month survival status resumption baseline activity Study Design - Single center , prospective , double blind , randomise control trial critically ill patient severe sepsis - Randomisation - A centralised randomisation system SCRI ( Singapore Clinical Research institute ) - Allocation random conceal , blind everyone except pharmacist site , responsible prepare deliver ICU blind fashion . - Intervention - Patients randomise receive glutamine supplementation receive IV glutamine ( 0.5g/kg body weight/day ) continuously 24 hour . - IV glutamine administer 5 day less death ensues prior 5 day transfer another hospital prior 5 day . IV glutamine continue even patient transfer outside ICU within hospital . - An intravenous saline solution identical volume , color consistency administer placebo group dose regimen duration . - Cointerventions - Nutritional support continue per manage ICU team discretion . - Management severe sepsis continue per manage ICU team discretion . - Weaning patient mechanical ventilation do per manage ICU team discretion . - To minimise difference center , active dissemination practice guideline nutritional support , sepsis management wean carry . Execution study protocol - The manage ICU team responsible identify patient meet inclusion exclusion criterion inform site research coordination - The site research coordinator responsible follow - Obtaining consent relatives patient - Informing site pharmacist recruit patient - Follow study patient prospectively ICU , hospital post discharge 3 6 month . - Completing case report study participant - Submitting case report form , complete interim report , coordinate statistical team - Pharmacist - Site pharmacist liase SCRI randomise patient status ( treatment vs. placebo ) - Prepare intervention treatment placebo - Deliver treatment placebo respective patient . - Nurses - Responsible administering deliver medication - Ensure document compliance administration , reason interruption document adverse reaction . - Liasing site research coordinator daily regard . - Liasing site research coordinator transfer , discharge death study participant</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<criteria>Inclusion Criteria All adult patient ( &gt; 18 year old ) admit ICU plus Severe sepsis define 2 follow Temperature &gt; 38oC &lt; 36oC Heart rate &gt; 90 beat per min Respiratory rate &gt; 20 breath per min PaCO2 &lt; 32 mmHg White cell count &gt; 12,000/microL &lt; 4,000/microL PLUS presence presume presence infection PLUS evidence organ dysfunction define either follow Hemodynamic : Hypotension = systolic blood pressure ( SBP ) 40 mm Hg mean arterial pressure ( MAP ) &lt; 65 mm Hg ; vasopressor Hyperlactatemia : Serum lactate &gt; /= 2 mmol/L ( 18 mg/dL ) Renal : Acute increase serum creatinine &gt; 176.8 mmol/L ( 2.0 mg/dL ) urine output &lt; 0.5 mL/kg/hour &gt; 2 hour Lung : Acute lung injury PaO2/FiO2 &lt; /=300mmHg Liver : Acute increase bilirubin &gt; /= 34.2 umol/L ( 2 mg/dL ) Thrombocytopenia : Acute decrease platelet count &lt; 100,000 cells/mm3 Coagulopathy : International normalized ratio ( INR ) &gt; 1.5 partial thromboplastin time ( aPTT ) &gt; 60 sec due anticoagulant therapy Exclusion criterion &gt; 48hr admission ICU Patients expect survive &gt; 48hrs manage team Refusal consent study Allergic glutamine constituent Absolute contraindication enteral nutrition need initiate parenteral nutrition Patients primary admission diagnosis burn ( &gt; 30 % body surface area ) Patients whose weight &lt; 40kg &gt; 200kg Previous randomization study Enrolled related ICU interventional nutrition study Pregnant patient lactate mother intent breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glutamine</keyword>
	<keyword>Severe sepsis</keyword>
</DOC>